Adherence to biomedical HIV prevention methods: Considerations drawn from HIV treatment adherence research

Current HIV/AIDS Reports

Volumn 5, Issue 4, 2008, Pages 186-192

  Stirratt, Michael J ^a   Gordon, Christopher M ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT;

ARTICLE; BIOMEDICINE; COGNITIVE THERAPY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; PATIENT COMPLIANCE; PREVENTIVE MEDICINE; SELF REPORT; SOCIAL ENVIRONMENT; SOCIAL SUPPORT; BEHAVIOR THERAPY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GENITAL HERPES; MALE; METHODOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; VIROLOGY;

ACYCLOVIR; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; BEHAVIOR THERAPY; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE;

EID: 58149161570     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-008-0027-z     Document Type: Article

References (46)

1. Holtgrave D: Evidence-based efforts to prevent HIV infection: an overview of current status and future challenges. Clin Infect Dis 2007, 45(Suppl 4):S293-S299.
2. Green EC, Halperin DT, Natulya V, Hogle JA: Uganda's HIV prevention success: the role of sexual behavior change and the national response. AIDS Behav 2006, 10:335-346.
3. Gray RH, Kigozi G, Serwadda D, et al.: Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007, 369:657-666.
4. Padian NS, van der Straten A, Ramjee G, et al.: Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 2007, 370:251-261.
5. Watson-Jones D, Weiss HA, Rusizoka M, et al.: Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008, 358:1560-1571.
6. Cohen J: Microbicide fails to protect against HIV. Science 2008, 319:1026-1027.
7. Peterson L, Taylor D, Roddy R, et al.: Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007, 2:e27.
8. Lagakos SW, Gable AR, eds: Methodological Challenges in Biomedical HIV Prevention Trials. Washington DC: National Academies Press; 2008. This IOM committee report summarizes the methodologic challenges in late-stage nonvaccine biomedical HIV prevention trials, with a special focus on microbicide and PrEP trials, along with recommendations for pretrial research and planning.
9. Giordano TP, Gifford AL, White AC, et al.: Retention in care: a challenge to survival with HIV infection. Clin Infect Dis 2007, 44:1493-1499.
10. Stirratt MJ, Gordon CM: HIV treatment adherence research and intervention: current advances and future challenges. J HIV/AIDS Soc Serv 2007, 6:9-22.
11. Bradford JB: The promise of outreach for engaging and retaining out-of-care persons in HIV medical care. AIDS Patient Care STDS 2007, 21(Suppl 1):S85-S91.
12. Fisher M: Late diagnosis of HIV infection: major consequences and missed opportunities. Curr Opin Infect Dis 2008, 21:1-3.
13. Branson BJ: Current HIV epidemiology and revised recommendations for HIV testing in health-care settings. Med Virol 2007, 79(Suppl 1):S6-S10.
14. Gao X, Nau DP, Rosenbluth SA, et al.: The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care 2000, 12:387-398.
15. Arnsten JH, Demas PA, Farzadegan H, et al.: Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001, 33:1417-1423.
16. Miller LG, Hays RD: Measuring adherence to antiretroviral medications in clinical trials. HIV Clin Trials 2000, 1:36-46.
17. Bell DJ, Kapitao Y, Sikwese R, et al.: Adherence to antiretroviral therapy in patients receiving free treatment from a government hospital in Blantyre, Malawi. J Acquir Immune Defic Syndr 2007, 45:560-563.
18. Chesney MA: The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr 2006, 43(Suppl 1):S149-S155.
19. Simoni JM, Kurth AE, Pearson, CR, et al.: Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav 2006, 10:227-245. Review of 77 self-report measures of ARV adherence, varying in item content, format, and response items, with recommended items and strategies for HIV research and clinical management.
20. Bangsberg DR, Bronstone A, Chesney MA, Hecht FM: Computer-assisted self-interviewing (CASI) to improve provider assessment of adherence in routine clinical practice. J Acquir Immune Defic Syndr 2002, 31(Suppl 3):S107-S111.
21. Chesney MA, Ickovics JR, Chambers DB, et al.: Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care 2000, 12:255-266.
22. Lu M, Safren SA, Skolnik PR, et al.: Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav 2008, 12:86-94.
23. Kalichman SC, Cain D, Fuhrel A, et al.: Assessing medication adherence self-efficacy among low-literacy patients: development of a pictographic visual analogue scale. Health Educ Res 2004, 20:24-35.
24. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al.: Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 2004, 36:1100-1102.
25. Hogarty K, Kasowitz A, Herold BC, Keller MJ: Assessment of adherence to product dosing in a pilot microbicide study. Sex Transm Dis 2007, 34:1000-1003.
26. Bangsberg DR, Hecht FM, Charlebois ED, et al.: Comparing objective measures of adherence to HIV antiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav 2001, 5:275-281.
27. Kalichman SC, Amarai CM, Stearns H, et al.: Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone. J Gen Int Med 2007, 22:1003-1006. Documents the high reliability of unannounced phone-based pill counts as an economically and logistically feasible objective method for monitoring medication adherence.
28. Liu H, Golin CE, Miller LG, et al.: A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001, 134:968-977.
29. Mills EJ, Nachega JB, Buchan I, et al.: Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006, 296:679-690.
30. Bangsberg DR, Ware N, Simoni J: Adherence without access to antiretroviral therapy in sub-Saharan Africa? AIDS 2006, 20:140-141.
31. Johnson KE, Quinn TC: Update on male circumcision: prevention success and challenges ahead. Curr Infect Dis Rep 2008, 10:243-251.
32. Oyugi JH, Byakika-Tusiime J, Ragland K, et al.: Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007, 21:965-971.
33. Ware NC, Wyatt MA, Tugenberg T: Social relationships, stigma and adherence to antiretroviral therapy for HIV/ AIDS. AIDS Care 2006, 18:904-910.
34. Ramadhani HO, Thielman NM, Landman KZ, et al.: Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis 2007, 45:1492-1498.
35. Behforouz HL, Farmer PE, Mukherjee JS: From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis 2004, 38(Suppl 5):S429-S436.
36. Simoni JM, Pearson CR, Pantalone DW, et al.: Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load: a meta-analytic review of randomized controlled trials. J Acquir Immune Defic Synd 2006, 43(Suppl 1):S23-S35. Evaluates the state of the science for HIV treatment adherence interventions, strengths and limitations of the interventions, and moderators of effect size.
37. Pradier C, Bentz L, Spire B, et al.: Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials 2003, 4:121-131.
38. Reynolds NR, Testa MA, Su M, et al.: Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial. J Acquir Immune Defic Synd 2008, 47:62-68.
39. Petersen ML, Wang Y, van der Laan MJ, et al.: Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis 2007, 45:908-915.
40. Celum C, Wald A, Hughes J, et al.: Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:2109-2119.
41. Remien RH, Stirratt MJ, Dolezal C, et al.: Couple-focused support to improve HIV medication adherence: a randomized controlled trial. AIDS 2005, 19:807-814.
42. Rosen MI, Dieckhaus K, McMahon TJ, et al.: Improved adherence with contingency management. AIDS Patient Care STDS 2007, 21:30-40.
43. Williams AB, Fennie KP, Bova CA, et al.: Home visits to improve adherence to highly active antiretroviral therapy: a randomized controlled trial. J Acquir Immune Defic Syndr 2007, 42:314-321.
44. Pearson CR, Micek MA, Simoni JM, et al.: Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr 2007, 46:238-244.
45. Goggin K, Liston RJ, Mitty JA: Modified directly observed therapy for antiretroviral therapy: a primer from the field. Public Health Rep 2007, 122:472-481.
46. Gray RH, Wawer MJ: Randomised trials of HIV prevention. Lancet 2007, 370:200-201.